Heron Therapeutics is trading 5.47% up at $0.33 in pre-market, with no clear company-specific catalyst identified for September 3, 2026.
- Latest available company coverage centers on August 10 second-quarter results and previously disclosed financial pressures, not a fresh overnight announcement.
- Broader futures are only modestly higher, while available evidence supports a low-confidence, potentially liquidity-driven increase.